Evidence map›Paper›PMID 35604614›Full record

ArticleBreast cancer (Tokyo, Japan)2022

Characteristics, treatment trends, and long-term outcomes of Japanese patients with pregnancy-associated breast cancer (PABC).

Akemi Kataoka, Takayuki Ueno, Hideko Yamauchi, Natsue Uehiro, Chikako Takahata, Yoko Takahashi, Eri Nakashima, Akiko Ogiya, Takehiko Sakai, Dai Kitagawa and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Impact of Pregnancy on Breast Cancer Features and Prognosis.Current oncology (Toronto, Ont.) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 1 country.

Akemi KataokaDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. akemi.kataoka@jfcr.or.jp.ORCID http://orcid.org/0000-0002-3156-2474
Takayuki UenoDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Hideko YamauchiDepartment of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan.
Natsue UehiroDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Chikako TakahataDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Yoko TakahashiDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Eri NakashimaDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Akiko OgiyaDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Takehiko SakaiDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Dai KitagawaDepartment of Breast Surgical Oncology, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
Hidetomo MorizonoDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Yumi MiyagiDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Takuji IwaseDepartment of Breast and Endocrine Surgery, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Atsuko KitanoDepartment of Medical Oncology, St. Luke's International Hospital, Tokyo, Japan.
Yumi FukatsuDepartment of Surgery, Kasukabe Medical Center, Saitama, Japan.
Nobuko TamuraDepartment of Breast Surgical Oncology, Toranomon Hospital, Tokyo, Japan.
Junko KawanoDepartment of Breast and Thyroid Surgical Oncology, Sagara Hospital, Kagoshima, Japan.
Hiroko BandoBreast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Kentaro TamakiDepartment of Breast Surgery, Nahanishi Clinic, Okinawa, Japan.
Kyoko ShiotaIntegrated Woman's Health, St. Luke's International Hospital, Tokyo, Japan.
Miwa OzawaDepartment of Pediatrics, St. Luke's International Hospital, Tokyo, Japan.
Mariko KobayashiThe Open University of Japan, Chiba, Japan.
Shinji OhnoDepartment of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Japanese Foundation For Cancer Research · JPSt. Luke's International Hospital · JPJapanese Red Cross Nagoya Daiichi Hospital · JPNational Center for Global Health and Medicine · JPNational Sagamihara Hospital · JPOsaka Nishi Clinic · JPSaitama Medical University · JPThe Open University of Japan · JPToranomon Hospital · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo clarify the characteristics, treatment trends, and long-term outcomes of patients with pregnancy-associated breast cancer (PABC).

methodsPABC includes breast cancer diagnosed during pregnancy (PBC) and breast cancer diagnosed within 1 year after childbirth or during lactation (LBC). We compared clinical characteristics of 126 patients with LBC and 49 patients with PBC who underwent surgery at our hospital from 1946 to 2018. Survival was compared between patients with LBC and those with PBC in terms of breast cancer-specific disease-free survival (BC-DFS) and overall survival (OS).

resultsPatients with LBC were more likely to have family history, lymph node metastasis, lymphatic invasion, and to receive chemotherapy than patients with PBC. Patients with LBC showed poorer BS-DFS and OS than patients with PBC. Among patients with LBC, those treated after 2005 were older at surgery, had a smaller tumor size, received more systemic therapy, and had a more favorable prognosis than patients treated before 2004. Family history, breast cancer within 1 year after childbirth, and surgery before 2004 as well as cStage, lymph node metastasis, and lymphatic invasion were significantly associated with poor prognosis in patients with LBC. In the multivariate analysis for BC-DFS and OS among patients with PABC, LBC vs PBC did not remain as an independent prognostic factor while cStage remained.

conclusionPatients with LBC had a poorer prognosis than those with PBC, most likely due to disease progression rather than biological characteristics. Early detection and optimization of systemic treatments are critical for improving the outcomes of patients with LBC.

Indexed as

Breast NeoplasmsPregnancy Complications, NeoplasticAzidesDisease-Free SurvivalFemaleHumansJapanLymphatic MetastasisPregnancyPrognosisPropanolaminesRetrospective Studies4-azidobenzylcarazololAzidesPropanolaminesBreast cancerChemotherapyChildbirthLactationPregnancyPrognosis

Identifiers

PMID35604614
OpenAlexW4281287096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.